Pulmonx Corp Stock Price, News & Analysis

On January 28, 2021, JTV, a national jewelry retailer, announced its partnership with the Respiratory Health Association and Pulmonx Corporation for the third annual Catch Your Breath® campaign. This initiative aims to raise awareness and funds for women's lung disease during February 2021, focusing on educational opportunities about lung health. The campaign includes a special event from January 29 to 31, where 50% of sales from the Catch Your Breath® butterfly jewelry collection will benefit lung health programs.

Pulmonx Corporation (NASDAQ: LUNG) has welcomed Georgia Garinois-Melenikiotou and Thomas W. Burns to its Board of Directors as part of its initial public offering in October 2020. Garinois-Melenikiotou brings significant experience in global consumer marketing from her tenure at Estée Lauder and Johnson & Johnson, while Burns offers over 25 years of experience in medical technology, currently serving as CEO of Glaukos Corporation. Their expertise is expected to enhance Pulmonx's efforts in expanding its market presence for innovative treatments for severe lung disease.

Pulmonx Corporation announced that over 20,000 patients have been treated globally with its Zephyr® Endobronchial Valves, the first FDA-approved minimally invasive treatment for severe emphysema. This treatment significantly improves lung function, exercise capacity, and overall quality of life without the risks associated with traditional surgery. Dr. D. Kyle Hogarth highlighted the Zephyr Valve's role in helping patients breathe easier. The device is now included in national and global COPD treatment guidelines, evidencing its acceptance and effectiveness in clinical practice.

Pulmonx Corporation (Nasdaq: LUNG) reported a 17% increase in revenue for Q3 2020, totaling $10.6 million. The gross margin remained stable at 70.3%. U.S. revenue surged by 57% to $5.3 million, driven by the Zephyr Valve launch, while international revenue dropped 8% due to pandemic impacts. Operating expenses rose 28% to $12.8 million, leading to a net loss of $3.9 million or $1.37 per share. Pulmonx expects full-year revenue between $31.5-$32.0 million, reflecting ongoing uncertainty from COVID-19.

Pulmonx Corporation (NASDAQ: LUNG) announced its participation in two virtual investor conferences. The company will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 10:40 a.m. ET, with a live and archived webcast available on its website. Additionally, Pulmonx management will join investor meetings at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020. Pulmonx specializes in minimally invasive treatments for severe emphysema, having received FDA pre-market approval for its Zephyr Endobronchial Valve.

Pulmonx Corporation (NASDAQ: LUNG) announced that Health Care Service Corporation (HCSC) has implemented a positive coverage policy for the Zephyr Endobronchial Valve effective November 1, 2020. This policy benefits Blue Cross Blue Shield members across Illinois, Montana, New Mexico, Oklahoma, and Texas. The Zephyr Valve offers a minimally invasive treatment for severe emphysema, improving lung function and quality of life without major surgery. Over 20,000 patients have been treated with this valve globally, highlighting its significance in COPD management.

Pulmonx Corporation (NASDAQ: LUNG) will release its third-quarter financial results on November 10, 2020, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. The company specializes in minimally invasive treatments for lung disease, particularly for severe emphysema/COPD patients. The Zephyr® Endobronchial Valve, part of its treatment solutions, has received FDA pre-market approval and is available in over 25 countries with more than 80,000 valves used on over 20,000 patients.

Pulmonx Corporation (Nasdaq: LUNG) recently closed its initial public offering, selling 11,500,000 shares of common stock at $19.00 per share. This includes the full exercise of underwriters' options for 1,500,000 additional shares. The gross proceeds from the offering reached approximately $218.5 million, prior to deductions for underwriting discounts and commissions. Shares began trading on The Nasdaq Global Select Market on October 1, 2020. BofA Securities and Morgan Stanley served as joint lead managers for the offering.

Pulmonx Corporation has announced the pricing of its upsized initial public offering (IPO) of 10,000,000 shares at $19.00 each, totaling gross proceeds of $190 million. The offering includes a 30-day option for underwriters to purchase an additional 1,500,000 shares. Trading on the Nasdaq under the symbol 'LUNG' will commence on October 1, 2020, with the expected close on October 5, 2020. BofA Securities and Morgan Stanley lead the offering, which was declared effective by the SEC on the same day.